Howmet Aerospace Inc vs Illumina, Inc. — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Howmet Aerospace Inc is far larger — about 2.2× Illumina, Inc.'s market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Illumina, Inc. for 83 Days on average.
| HWM | ILMN | |
|---|---|---|
Market Cap | $88.76B | $39.95B |
Volume | 2,648,516 | 3,169,503 |
Sector | Industrials | Health |
52-Week High | $292.65 | $293.69 |
52-Week Low | $184.09 | $91.00 |
Typical Hold Time | 35 Days | 83 Days |
Enterprise Value | $92.86B | $41.31B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $222.53, down 0.08% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with revenue and earnings growth, a net income margin of 20.52%, and consistent quarterly EPS beats. Analyst consensus is overwhelmingly bullish with a $328.10 price target, supported by positive news on defense and aerospace demand.
The outlook for HWM is positive due to robust financial performance and sector tailwinds, but risks include technical weakness and competitive pressures. Investment opportunity lies in its growth trajectory and shareholder returns, though investors should monitor execution risks and market volatility.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →